加利福尼亚州千橡市和英格兰牛津——(2018年10月18日)——安进公司(纳斯达克：AMGN)和Oxford Nanopore Technologies Ltd今天宣布安进对Oxford Nanopore进行 5000万英镑(6600万美元)的股权投资。Oxford Nanopore是一家设立在英国的私营企业，致力于推进新一代便携式实时基因测序技术。
Oxford Nanopore开发出了一款自有测序技术并已将其推向市场，该技术结合使用多个纳米孔(由合成膜中包含的蛋白质制成的纳米级孔)以及电子学原理，对DNA和RNA进行直接实时测序。这项技术所对应的设备范围包括从袖珍式到高通量台式，可对非常长的DNA或RNA片段进行测序，在基因组分析中具有诸多益处。
对Oxford Nanopore的投资符合安进的战略重点，即利用人类遗传学向患者提供新药。安进的子公司deCODE Genetics是人类遗传学领域的全球领军者，它使用Oxford Nanopore的测序技术进行基因组研究，其中包括发掘和验证新靶点。
deCODE Genetics的创始人Kári Stefánsson说：“人类遗传学的研究不断地揭示我们社会所面临的疾病的深刻洞察。Oxford Nanopore的长读长测序能力为我们一直以来都无法了解的基因组部分开创了一扇窗口，同时也为我们提供了一种更好的方法，对带来多种疾病风险的结构变异进行分析。我们已经用Oxford Nanopore技术测序了数百个人类基因组，并持续地看到这项新兴技术的前景。”
Oxford Nanopore的首席执行官戈登·桑格拉(Gordon Sanghera)说：“作为生物技术的先驱，安进展示了通过创新和对遗传学的深入理解可以为社会取得哪些成就。我们很高兴欢迎他们成为股东。”
纳米孔技术具有独特的可扩展性。MinIONTM是唯一的一款袖珍测序仪，可用于在任何地点进行测序。此外，Oxford Nanopore公司开发了台式、按需、高通量设备，如专为大型项目或大量样本设计的PromethIONTM。
这项投资将通过购买Oxford Nanopore的5000万英镑(6600万美元)普通股来实现，每股价格与2018年3月宣布的新股募资轮相同。
关于安进 (Amgen)
安进致力于通过发掘、开发、制造和提供创新型的人类疗法，为患有严重疾病的患者释放生物学的潜力。这种方法始于使用先进的人类遗传学工具来揭示疾病的复杂性，并了解人类生物学的基本原理。
安进专注于医疗需求未能够满足的领域，并利用其专业知识努力寻求改善健康结果和显着改善人们生活的解决方案。作为自1980年以来的生物技术先驱，安进已发展成为世界领先的独立生物技术公司之一，已覆盖全球数百万患者，并正在开发具有突破潜力的药物管道。
关于deCODE Genetics
deCODE总部位于冰岛雷克雅未克，是分析和理解人类基因组的全球领导者。利用其独特的专业知识和人口资源，deCODE发现了数十种常见疾病的遗传风险因素。理解疾病遗传学的目的，是利用该信息创造诊断、治疗和预防疾病的新方法。 deCODE是安进的全资子公司。
关于Oxford Nanopore
Oxford Nanopore Technologies旨在通过易于获取和使用的高性能新型DNA/RNA测序技术来颠覆生物分析的模式。其目标是让任何人能在任何环境中对任何生物进行基因分析。
Oxford Nanopore Technologies基于电子学的新型DNA/RNA测序技术正应用于80多个国家的一系列生物研究中，其中包括大规模人类基因组学、癌症研究、微生物学、植物科学和环境研究。
Oxford Nanopore Technologies也在探索纳米孔测序在科研之外的应用，它有潜力在医疗保健、农业、食品与水监测及教育领域提供快速、有意义的信息。
安进(Amgen) 前瞻性陈述
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen project. Amgen’s results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen’s products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen’s business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen’s business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. While Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for Amgen’s products are supplied by sole third-party suppliers. Certain of Amgen’s distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen’s efforts to acquire other companies or products and to integrate the operations of companies Amgen has acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of Amgen’s systems and Amgen’s data. Amgen’s stock price may be volatile and may be affected by a number of events. Amgen’s business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all.
